Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.
- DOI
- 10.1016/j.bpobgyn.2022.02.002
- Published
- 2022 Dec
- Container
- Best practice & research. Clinical obstetrics & gynaecology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bpobgyn.2022.02.002,
title = {Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.},
author = {Bühler K and Roeder C and Schwarze JE and Lispi M and Allignol A and Falla E and Lukyanov V and D Hooghe T and Fischer R},
year = {2022},
journal = {Best practice \& research. Clinical obstetrics \& gynaecology},
doi = {10.1016/j.bpobgyn.2022.02.002},
url = {https://doi.org/10.1016/j.bpobgyn.2022.02.002}
}RIS
TY - JOUR TI - Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry. AU - Bühler K AU - Roeder C AU - Schwarze JE AU - Lispi M AU - Allignol A AU - Falla E AU - Lukyanov V AU - D Hooghe T AU - Fischer R PY - 2022 JO - Best practice & research. Clinical obstetrics & gynaecology DO - 10.1016/j.bpobgyn.2022.02.002 UR - https://doi.org/10.1016/j.bpobgyn.2022.02.002 ER -
APA
K, B., C, R., JE, S., M, L., A, A., E, F., V, L., T, D. H., & R, F. (2022). Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.. Best practice & research. Clinical obstetrics & gynaecology. https://doi.org/10.1016/j.bpobgyn.2022.02.002
Source records
- pubmed · retrieved 2026-09-27T07:01:07.998Z